The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic ...

Zanidatamab-hrii received FDA accelerated approval for HER2-positive biliary tract cancer, showing a 52% objective response rate in the HERIZON-BTC-01 trial. Biliary tract cancers represent 3% of ...

Compass Therapeutics' tovecimig shows promise in biliary tract cancer with a 17.1% response rate, but further survival data is crucial for potential approval. CMPX's cash runway extends into early ...

An update from Sino Biopharmaceutical ( (HK:1177)) is now available. Sino Biopharmaceutical’s subsidiary Chia Tai Tianqing has reported positive Phase III results for TQB3454, an IDH1 inhibitor ...

Findings showed that pembrolizumab plus chemotherapy reduced the risk of death by 17% compared with chemotherapy alone. The Food and Drug Administration (FDA) has approved Keytruda ® (pembrolizumab) ...

Rachna T. Shroff, MD, addresses the impact of health disparities in the treatment outcomes of patients with cancer. Specifically discussing patients with biliary tract cancer, Dr Shroff focuses ...

Results showed the ORR was 17.1% in the tovecimig plus paclitaxel arm compared with 5.3% in the paclitaxel alone arm. Topline data were announced from a phase 2/3 trial evaluating tovecimig in ...

Biliary tract cancer is increasing in incidence and mortality across Europe, with more people under the age of 60 years old now impacted by the disease. However, despite this, knowledge about these ...

Please provide your email address to receive an email when new articles are posted on . The FDA granted accelerated approval to zanidatamab-hrii for treatment of adults with previously treated ...

ctDNA is a valuable prognostic biomarker for relapse in early-stage BTC, outperforming carbohydrate antigen 19-9 levels. ctDNA monitoring can detect molecular recurrence earlier than standard ...

Compass Therapeutics (CMPX) is back on investors’ radar after fresh analysis of the biliary tract cancer market highlighted its lead candidate CTX-009 as a key emerging therapy in this growing ...

The FDA on Wednesday granted accelerated approval to zanidatamab (Ziihera), a bispecific antibody, for pretreated HER2-positive biliary tract cancer. Approval stipulates use in unresectable or ...